Exact Sciences Corp. (NASDAQ:EXAS) was a big mover last session, as the company saw its shares jump almost 12% on the day. The upside was driven by the news from UnitedHealth that it would fund the Exact Sciences' Cologuard test expenses for colon cancer. Also, this led to far more shares changing hands than in a normal session. This breaks the recent trend for the company as the stock is now trading above the volatile price range of $30.33 to $35.43 in the past one-month time frame.
The company has seen two positive estimate revisions in the past 30 days. Also, its Zacks Consensus Estimate moved higher over the same timeframe. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Exact Sciences currently carries a Zacks Rank #3 (Hold).
Exact Sciences Corporation Price
A better-ranked stock in the Medical – Biomedical and Genetics industry is Aimmune Therapeutics, Inc. (NASDAQ:AIMT) , which holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Is EXAS going up? Or down? Predict to see what others think: Up or Down
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Exact Sciences Corporation (EXAS): Free Stock Analysis Report
Aimmune Therapeutics, Inc. (AIMT): Free Stock Analysis Report
Original post
Zacks Investment Research